Australia : CAR-T cell therapy patent disputes
Language: English Analytics: Show analyticsPublisher: 22 June 2022Description: 3 pSubject(s): Genre/Form: Online Resources: E-Resource Local URL: SNIPER Full Text In: World Intellectual Property ReviewSNIPER Journal Article
Accessed 23 June 2022 as free to read article.
Will litigation over the ground-breaking cancer technology seen elsewhere reach the Australian market? -- Chimeric Antigen Receptor (CAR)-T cell therapy is a pioneering technology that is successfully changing the way we think about the treatment of cancer, in particular blood cancers. A number of CAR-T cell therapies have been approved in the US, Europe and Australia -- Currently, there are five approved CAR-T cell therapies in the US, four in Europe and three in Australia -- While CAR-T patent disputes have not yet hit the Australian or European Courts, they have already commenced in the US
Creative Commons Attribution 4.0 International (CC BY 4.0)
| Item type | Current library | Call number | Status | Date due | Barcode | Item holds | |
|---|---|---|---|---|---|---|---|
| SNIPER | IP Australia Library SNIPER Articles | 2022/00203 (Browse shelf(Opens below)) | Available | 200802853 |
Browsing IP Australia Library shelves, Shelving location: SNIPER Articles Close shelf browser (Hides shelf browser)
There are no comments on this title.